B-physics from the ratio method with Wilson twisted mass fermions

We present a precise lattice QCD determination of the b-quark mass, of the B and Bs decay constants and first preliminary results for the B-mesons bag parameter. Simulations are performed with Nf = 2 Wilson twisted mass fermions at four values of the lattice spacing and the results are extrapolated to the continuum limit. Our calculation benefits from the use of improved interpolating operators for the B-mesons and employs the so-called ratio method. The latter allows a controlled interpolation at the b-quark mass between the relativistic data around and above the charm quark mass and the exactly known static limit.Comment: 7 pages, 4 figures, 1 table. Proceedings of the 30th International Symposium on Lattice Field Theory - Lattice 2012; June 24-29, 2012; Cairns, Australi

B-physics from lattice QCD...with a twist

We present a precise lattice QCD determination of the b-quark mass, of the B and Bs decay constants and first results for the B-meson bag parameters. For our computation we employ the so-called ratio method and our results benefit from the use of improved interpolating operators for the B-mesons. QCD calculations are performed with Nf = 2 dynamical light-quarks at four values of the lattice spacing and the results are extrapolated to the continuum limit. The preliminary results are mb(mb) = 4.35(12) GeV for the MSbar b-quark mass, fBs = 234(6) MeV and fB = 197(10) MeV for the B-meson decay constants, BBs(mb) = 0.90(5) and BB(mb) = 0.87(5) for the B-meson bag parameters.Comment: 6 pages, 3 figures. Proceedings of the 36th International Conference on High Energy Physics - ICHEP 2012; July 4-11 2012; Melbourne, Australi

Lattice QCD determination of m_b, f_B and f_Bs with twisted mass Wilson fermions

We present a lattice QCD determination of the b quark mass and of the B and B_s decay constants, performed with N_f=2 twisted mass Wilson fermions, by simulating at four values of the lattice spacing. In order to study the b quark on the lattice, two methods are adopted in the present work, respectively based on suitable ratios with exactly known static limit and on the interpolation between relativistic data, evaluated in the charm mass region, and the static point, obtained by simulating the HQET on the lattice. The two methods provide results in good agreement. For the b quark mass in the MSbar scheme and for the decay constants we obtain m_b(m_b)=4.29(14) GeV, f_B=195(12) MeV, f_Bs=232(10) MeV and f_Bs/f_B=1.19(5). As a byproduct of the analysis we also obtain the results for the f_D and f_Ds decay constants: f_D=212(8) MeV, f_Ds=248(6) MeV and f_Ds/f_D=1.17(5).Comment: 23 pages, 10 figures, 2 tables. Added appendix showing the agreement of the data for the ratios with the HQE prediction. Matching JHEP published versio

Light quark masses and pseudoscalar decay constants from Nf=2 Lattice QCD with twisted mass fermions

We present the results of a lattice QCD calculation of the average up-down and strange quark masses and of the light meson pseudoscalar decay constants with Nf=2 dynamical fermions. The simulation is carried out at a single value of the lattice spacing with the twisted mass fermionic action at maximal twist, which guarantees automatic O(a)-improvement of the physical quantities. Quark masses are renormalized by implementing the non-perturbative RI-MOM renormalization procedure. Our results for the light quark masses are m_ud^{msbar}(2 GeV)= 3.85 +- 0.12 +- 0.40 MeV, m_s^{msbar}(2 GeV) = 105 +- 3 +- 9 MeV and m_s/m_ud = 27.3 +- 0.3 +- 1.2. We also obtain fK = 161.7 +- 1.2 +- 3.1 MeV and the ratio fK/fpi=1.227 +- 0.009 +- 0.024. From this ratio, by using the experimental determination of Gamma(K-> mu nu (gamma))/Gamma(pi -> mu nu (gamma)) and the average value of |Vud| from nuclear beta decays, we obtain |Vus|=0.2192(5)(45), in agreement with the determination from Kl3 decays and the unitarity constraint.Comment: 20 pages, 5 figure

B-physics from Nf=2 tmQCD: the Standard Model and beyond

We present a lattice QCD computation of the b-quark mass, the B and B_s decay constants, the B-mixing bag parameters for the full four-fermion operator basis as well as determinations for \xi and f_{Bq}\sqrt{B_i^{(q)}} extrapolated to the continuum limit and to the physical pion mass. We used N_f = 2 twisted mass Wilson fermions at four values of the lattice spacing with pion masses ranging from 280 to 500 MeV. Extrapolation in the heavy quark mass from the charm to the bottom quark region has been carried out on ratios of physical quantities computed at nearby quark masses, exploiting the fact that they have an exactly known infinite mass limit. Our results are m_b(m_b, \overline{\rm{MS}})=4.29(12) GeV, f_{Bs}=228(8) MeV, f_{B}=189(8) MeV and f_{Bs}/f_B=1.206(24). Moreover with our results for the bag-parameters we find \xi=1.225(31), B_1^{(s)}/B_1^{(d)}=1.01(2), f_{Bd}\sqrt{\hat{B}_{1}^{(d)}} = 216(10) MeV and f_{Bs}\sqrt{\hat{B}_{1}^{(s)}} = 262(10) MeV. We also computed the bag parameters for the complete basis of the four-fermion operators which are required in beyond the SM theories. By using these results for the bag parameters we are able to provide a refined Unitarity Triangle analysis in the presence of New Physics, improving the bounds coming from B_{(s)}-\bar B_{(s)} mixing

Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia:Phase 2 Part B Study

Current treatments for persistent or chronic immune thrombocytopenia (ITP) are limited by inadequate response, toxicity, and impaired quality of life. The Bruton tyrosine kinase inhibitor rilzabrutinib was evaluated to further characterize safety and durability of platelet response. LUNA2 Part B is a multicenter, phase 1/2 study in adults with ITP (≥ 3 months duration, platelet count &lt; 30 × 109/L) who failed ≥ 1 ITP therapy (NCT03395210, EudraCT 2017–004012-19). Oral rilzabrutinib 400 mg bid was given over 24 weeks, with optional long-term extension (LTE). Primary endpoints were safety and platelet counts ≥ 50 × 109/L on ≥ 8 of the last 12 weeks of main treatment without rescue medication. From 22 March2018 to 31 January2023, 26 patients were enrolled. Patients had baseline median platelet count 13 × 109/L, ITP duration 10.3 years, and six prior ITP therapies (46% splenectomized). Nine (35%) patients achieved the primary endpoint. Platelet counts ≥ 50 × 109/L or ≥ 30 × 109/L and doubling from baseline without rescue therapy were sustained for a mean 9.3 weeks. 11 (42%) LTE-eligible patients were ongoing with median LTE platelet &gt; 80 × 109/L. Three (12%) patients received rescue medication during main treatment, none in LTE. Clinically meaningful improvements were observed in fatigue and women's health. With a median treatment duration of 167 days (main treatment), 16 (62%) patients had ≥ 1 treatment-related adverse event (AE), mainly grade 1, including diarrhea (35%), headache (23%), and nausea (15%). There was no treatment-related grade ≥ 2 bleeding/thrombotic events/infections, serious AE, or death. Rilzabrutinib continues to demonstrate durable platelet responses with favorable safety profile in previously treated ITP patients. Trial Registration: NCT03395210, EudraCT 2017-004012-19.</p

Hyperoxemia and excess oxygen use in early acute respiratory distress syndrome: insights from the LUNG SAFE study

Contains fulltext : 218568.pdf (publisher's version ) (Open Access)BACKGROUND: Concerns exist regarding the prevalence and impact of unnecessary oxygen use in patients with acute respiratory distress syndrome (ARDS). We examined this issue in patients with ARDS enrolled in the Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE (LUNG SAFE) study. METHODS: In this secondary analysis of the LUNG SAFE study, we wished to determine the prevalence and the outcomes associated with hyperoxemia on day 1, sustained hyperoxemia, and excessive oxygen use in patients with early ARDS. Patients who fulfilled criteria of ARDS on day 1 and day 2 of acute hypoxemic respiratory failure were categorized based on the presence of hyperoxemia (PaO2 > 100 mmHg) on day 1, sustained (i.e., present on day 1 and day 2) hyperoxemia, or excessive oxygen use (FIO2 >/= 0.60 during hyperoxemia). RESULTS: Of 2005 patients that met the inclusion criteria, 131 (6.5%) were hypoxemic (PaO2 < 55 mmHg), 607 (30%) had hyperoxemia on day 1, and 250 (12%) had sustained hyperoxemia. Excess FIO2 use occurred in 400 (66%) out of 607 patients with hyperoxemia. Excess FIO2 use decreased from day 1 to day 2 of ARDS, with most hyperoxemic patients on day 2 receiving relatively low FIO2. Multivariate analyses found no independent relationship between day 1 hyperoxemia, sustained hyperoxemia, or excess FIO2 use and adverse clinical outcomes. Mortality was 42% in patients with excess FIO2 use, compared to 39% in a propensity-matched sample of normoxemic (PaO2 55-100 mmHg) patients (P = 0.47). CONCLUSIONS: Hyperoxemia and excess oxygen use are both prevalent in early ARDS but are most often non-sustained. No relationship was found between hyperoxemia or excessive oxygen use and patient outcome in this cohort. TRIAL REGISTRATION: LUNG-SAFE is registered with ClinicalTrials.gov, NCT02010073